PRLD
vs
S&P 500
PRLD
S&P 500
Over the past 12 months, PRLD has significantly outperformed S&P 500, delivering a return of +73% compared to the S&P 500's +14% growth.
Stocks Performance
PRLD vs S&P 500
Performance Gap
PRLD vs S&P 500
Performance By Year
PRLD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Prelude Therapeutics Inc
Glance View
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. The company is headquartered in Wilmington, Delaware and currently employs 116 full-time employees. The company went IPO on 2020-09-25. The firm is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers. Its drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders. The firm is developing therapies in both solid tumors and hematological malignancies, such as adenoid cystic carcinoma (ACC), homologous recombination deficient positive (HRD+), cancers, myelofibrosis (MF) and glioblastoma multiforme (GBM), amongst others. The Company’s product candidates include PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT-K4.